Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citationBolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes.
Cranston, I., Lomas, J., Amiel, S. A., Maran, A., & Macdonald, I. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91336-6 · Cited by 430
Limitations of Conventional Methods of Self-Monitoring of Blood Glucose
Boland, E., Monsod, T., Delucia, M., Brandt, C. A., Fernando, S., & Tamborlane, W. V. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1858 · Cited by 423
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112884 · Cited by 394 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationEffect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.
Amiel, S. A., Sherwin, R. S., Simonson, D. C., & Tamborlane, W. V. (1988) · Diabetes · doi:10.2337/diab.37.7.901 · Cited by 393
White, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391 · cited 1×
“Patients with combined deficiencies of their glucagon and epinephrine responses have been shown in prospective studies to be at 25-fold, or at an even higher risk for severe iatrogenic hypoglycaemia during aggressive glycaemic therapy than those with absent glucagon but normal epinephrine responses [25, 26].”
BackgroundSelf-citationAbraira, C., Colwell, J. A., Nuttall, F. Q., Sawin, C. T., Nagel, N. J., Comstock, J. P., Emanuele, N. V., Levin, S. R., Henderson, W., Lee, H. S., et al. (1995) · Diabetes Care · doi:10.2337/diacare.18.8.1113 · Cited by 355
Hypoglycemia-associated autonomic failure in advanced type 2 diabetes.
Segel, S. A., Paramore, D. S., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.3.724 · Cited by 337 · cited 3×
“In these patients with insulin deficient Type II diabetes the glucagon response to hypoglycaemia was virtually absent [ 54 ].”
BackgroundInfluentialSelf-citationReversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM.
Dagogo-Jack, S., Rattarasarn, C., & Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.12.1426 · Cited by 328
Self-citationHypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
Self-citationBlood—Brain Barrier Glucose Transporter: Effects of Hypo‐ and Hyperglycemia Revisited
Simpson, I. A., Appel, N. M., Hokari, M., Oki, J., Holman, G. D., Maher, F., Koehler‐Stec, E. M., Vannucci, S. J., & Smith, Q. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720238.x · Cited by 304
Boyle, P. J., Schwartz, N. S., Shah, S. D., Clutter, W. E., & Cryer, P. E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182302 · Cited by 258
Self-citationFrequency and Morbidity of Severe Hypoglycaemia in Insulin‐treated Diabetic Patients
MacLeod, K. M., Hepburn, D. A., & Frier, B. M. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00051.x · Cited by 251
Cryer, P. E. (1992) · Diabetes · doi:10.2337/diab.41.3.255 · Cited by 231
Self-citationReversibility of unawareness of hypoglycemia in patients with insulinomas.
Mitrakou, A., Fanelli, C., Veneman, T., Perriello, G., Calderone, S., Platanisiotis, D., Rambotti, A., Raptis, S., Brunetti, P., Cryer, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309163291203 · Cited by 221
Self-citationBoyle, P. J., Kempers, S. F., O'Connor, A. M., & Nagy, R. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332602 · Cited by 221
REICHARD, P., BERGLUND, B., BRITZ, A., CARS, I., NILSSON, B. Y., & ROSENQVIST, U. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00415.x · Cited by 220
Fanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Di Vincenzo, A., Modarelli, F., Ciofetta, M., Lepore, M., Annibale, B., Torlone, E., et al. (1994) · Diabetologia · doi:10.1007/bf00399801 · Cited by 212 · cited 2×
“... epinephrine and glucagon concentrations during hyperinsulinaemic stepped hypoglycaemic clamps in patients with Type I diabetes studied the morning after clamped hyperglycemia the previous day on one occasion (� , � ) and after clamped hypoglycaemia the previous day on another occasion (� , � ). Reproduced from ref…”
MethodResultAdaptation in brain glucose uptake following recurrent hypoglycemia.
Boyle, P. J., Nagy, R. J., O'Connor, A. M., Kempers, S. F., Yeo, R. A., & Qualls, C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9352 · Cited by 208 · cited 1×
“Using the Kety-Schmidt technique, it has been reported that 56 h of interprandial hypoglycaemia increased brain glucose uptake during hypoglycaemia in non-diabetic subjects [39] and that brain glucose uptake during hypoglycaemia was preserved in patients with well controlled (ie.”
MethodBanarer, S., McGregor, V. P., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.4.958 · Cited by 194
Self-citationFanelli, C., Pampanelli, S., Epifano, L., Rambotti, A. M., Ciofetta, M., Modarelli, F., Di Vincenzo, A., Annibale, B., Lepore, M., Lalli, C., et al. (1994) · Diabetologia · doi:10.1007/bf00404337 · Cited by 193
An Introduction to the Study of Experimental Medicine
Wright, J. (1927) · Science · doi:10.1126/science.66.1715.453-a · Cited by 185
Davis, S. N., Shavers, C., Costa, F., & Mosqueda-Garcia, R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118839 · Cited by 173 · cited 15×
“It has been suggested that the cortisol response to antecedent hypoglycaemia mediates HAAF [34, 35, 36].”
BackgroundInfluentialCounterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167 · cited 1×
“Glucagon responses to hypoglycaemia have been reported to be normal [48, 49, 50] or reduced but not absent [51, 52, 53] in studies of unselected patients with Type II diabetes.”
BackgroundCounterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Hypoglycemia-Associated Autonomic Failure in Insulin-Dependent Diabetes Mellitus
Cryer, P. E. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60827-3 · Cited by 163
Self-citationHepburn, D. A., MacLeod, K. M., Pell, A. C. H., Scougal, I. J., & Frier, B. M. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00050.x · Cited by 156
Saudek, C. D. (1996) · JAMA · doi:10.1001/jama.276.16.1322 · Cited by 154
Hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1115 · Cited by 152 · cited 16×
“It has been suggested that the cortisol response to antecedent hypoglycaemia mediates HAAF [34, 35, 36].”
BackgroundInfluentialSelf-citationFukuda, M., Tanaka, A., Tahara, Y., Ikegami, H., Yamamoto, Y., Kumahara, Y., & Shima, K. (1988) · Diabetes · doi:10.2337/diab.37.1.81 · Cited by 145
Counterregulatory adaptation to recurrent hypoglycemia in normal humans
DAVIS, M. R., & SHAMOON, H. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-995 · Cited by 143
A reliable and reproducible test for adequate glucose counterregulation in type I diabetes mellitus.
Bolli, G. B., Feo, P. D., Cosmo, S. D., Perriello, G., Ventura, M. M., Benedetti, M. M., Santeusanio, F., Gerich, J. E., & Brunetti, P. (1984) · Diabetes · doi:10.2337/diab.33.8.732 · Cited by 124
Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes.
Fanelli, C. G., Paramore, D. S., Hershey, T., Terkamp, C., Ovalle, F., Craft, S., & Cryer, P. E. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1920 · Cited by 119
Self-citationBolli, G. B., Feo, P. D., Compagnucci, P., et al. (1983) · Diabetes · doi:10.2337/diabetes.32.2.134 · Cited by 118
Mühlhauser, I., Overmann, H., Bender, R., Bott, U., & Berger, M. (1998) · Diabetologia · doi:10.1007/s001250051065 · Cited by 117 · cited 1×
“Risk factors related to compromised glucose counterregulation that are well established in Type I diabetes [1, 23, 58 ] and are likely to be relevant in advanced Type II diabetes, include: (i) insulin deficiency; (ii) a history of severe hypoglycaemia, hypoglycaemia unawareness, or both; (iii) aggressive glycaemic the…”
BackgroundOvalle, F., Fanelli, C. G., Paramore, D. S., Hershey, T., Craft, S., & Cryer, P. E. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1472 · Cited by 117
Self-citationSegel, S. A., Fanelli, C. G., Dence, C. S., Markham, J., Videen, T. O., Paramore, D. S., Powers, W. J., & Cryer, P. E. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1911 · Cited by 109
Self-citationBolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108 · cited 1×
“Glucagon responses to hypoglycaemia have been reported to be normal [48, 49, 50] or reduced but not absent [51, 52, 53] in studies of unselected patients with Type II diabetes.”
BackgroundSelf-citationEffects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia
Galassetti, P., Mann, S., Tate, D., Neill, R. A., Costa, F., Wasserman, D. H., & Davis, S. N. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.6.e908 · Cited by 108
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release
Amiel, S. A., Sherwin, R. S., Simonson, D. C., et al. (1988) · Diabetes · doi:10.2337/diabetes.37.7.901 · Cited by 99
Davis, S. N., Shavers, C., Davis, B., & Costa, F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119550 · Cited by 98
Hypoglycemia: Pathophysiology, Diagnosis, and Treatment
Cryer, P. E. (1997) · Medical Entomology and Zoology · Cited by 86
Self-citationRandom C-peptide in the classification of diabetes
B. Berger, G. S. (2000) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510050216411 · Cited by 85
Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM
Dagogo-Jack, S. E., Rattarasarn, C., & Cryer, P. E. (1994) · Diabetes · doi:10.2337/diabetes.43.12.1426 · Cited by 71
Self-citationNegotiating the Barrier of Hypoglycemia in Diabetes
Cryer, P. E., & Childs, B. P. (2002) · Diabetes Spectrum · doi:10.2337/diaspect.15.1.20 · Cited by 65
Self-citationShamoon, H., Friedman, S., Canton, C., Zacharowicz, L., Hu, M., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117267 · Cited by 57
Cryer, P. E. (1992) · Diabetes · doi:10.2337/diabetes.41.3.255 · Cited by 56
Self-citationLimited Impact of Vigorous Exercise on Defenses Against Hypoglycemia
McGregor, V. P., Greiwe, J. S., Banarer, S., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1485 · Cited by 44
Self-citationHeller, S. R., Macdonald, I. A., & Tattersall, R. B. (1987) · Diabetologia · doi:10.1007/bf00295875 · Cited by 43 · cited 1×
“Glucagon responses to hypoglycaemia have been reported to be normal [48, 49 , 50] or reduced but not absent [51, 52, 53] in studies of unselected patients with Type II diabetes.”
BackgroundBoden, G., Soriano, M., Hoeldtke, R. D., & Owen, O. E. (1983) · Diabetes · doi:10.2337/diab.32.11.1055 · Cited by 43
Boden, G., Soriano, M., Hoeldtke, R. D., & Owen, O. E. (1983) · Diabetes · doi:10.2337/diabetes.32.11.1055 · Cited by 43
Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycemia?
Peacey, S. R., Robinson, R., Bedford, C., Harris, N. D., Macdonald, I. A., Holman, R. R., & Heller, S. R. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.1022 · Cited by 11
Hypoglycemia-Associated Autonomic Failure in Diabetes
Cryer, P. E., & Arbeláez, A. M. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_13 · Cited by 5
Self-citation(1996) · European Heart Journal · doi:10.1093/eurheartj/17.suppl_5.536 · Cited by 2
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes (289).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Hypoglycemia is the leading limiting factor in the glycemic management of type 1 and insulin-treated type 2 diabetes (223).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
“as normal a glycaemic profile as possible without unacceptable weight gain or hypoglycaemia [73].”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.